期刊
CYTOTHERAPY
卷 18, 期 11, 页码 1435-1445出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.jcyt.2016.09.003
关键词
-
类别
资金
- Welcome Trust [WT107963AIA]
- Rosetrees Trust
- Welton Foundation
- Roy Castle Lung Cancer Foundation
- University College London Hospital (UCLH) Charitable foundation
- MRC DPFS scheme [MR/M015831/1]
- Department of Health's National Institute for Health Research Biomedical Research Centre's funding scheme
- UCL Experimental Cancer Medicine Centre (ECMC)
- Cancer Research UK (CRUK) Lung Cancer Centre of Excellence (SMJ)
- MRC [G1000355, MR/M015831/1] Funding Source: UKRI
- Medical Research Council [MR/M015831/1, G1000355] Funding Source: researchfish
- National Institute for Health Research [CL-2014-18-001] Funding Source: researchfish
The cell therapy industry has grown rapidly over the past 3 decades, and multiple clinical trials have been performed to date covering a wide range of diseases. The most frequently used cell is mesenchymal stromal cells (MSCs), which have been used largely for their anti-inflammatory actions and in situations of tissue repair and although they have demonstrated a good safety profile, their therapeutic efficacy has been limited. In addition to these characteristics MSCs are being used for their homing and engraftment properties and have been genetically modified to enable targeted delivery of a variety of therapeutic agents in both malignant and nonmalignant conditions. This review discusses the science and technology behind genetically modified MSC therapy in malignant disease and how potential problems have been overcome to enable their use in two novel clinical trials in metastatic gastrointestinal and lung cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据